-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al. -
Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trialZ Ge, JJ Zhang, SL Chen et al.
-
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS TrialFox KAA, Eikelboom JW, Yusuf S et al.
-
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary InterventionJD McClure, JC Ramsay , C Berry et al.
-
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCIK Takahashi, PW Serruys, P Chichareont et al.
-
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial InfarctionS-J Lee, JY Cho, TICO Investigators et al.
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al.
-
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journeyD Cao, R Chandiramani, M Chiarito et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
